Glucose and leptin induce apoptosis in human beta-cells and impair glucose-stimulated insulin secretion through activation of c-Jun N-terminal kinases by Maedler, K et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
Glucose and leptin induce apoptosis in human beta-cells and
impair glucose-stimulated insulin secretion through activation of
c-Jun N-terminal kinases
Maedler, K; Schulthess, F T; Bielman, C; Berney, T; Bonny, C; Prentki, M; Donath, M
Y; Roduit, R
Maedler, K; Schulthess, F T; Bielman, C; Berney, T; Bonny, C; Prentki, M; Donath, M Y; Roduit, R (2008).
Glucose and leptin induce apoptosis in human beta-cells and impair glucose-stimulated insulin secretion through
activation of c-Jun N-terminal kinases. FASEB Journal, 22(6):1905-1913.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
FASEB Journal 2008, 22(6):1905-1913.
Maedler, K; Schulthess, F T; Bielman, C; Berney, T; Bonny, C; Prentki, M; Donath, M Y; Roduit, R (2008).
Glucose and leptin induce apoptosis in human beta-cells and impair glucose-stimulated insulin secretion through
activation of c-Jun N-terminal kinases. FASEB Journal, 22(6):1905-1913.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
FASEB Journal 2008, 22(6):1905-1913.
Glucose and leptin induce apoptosis in human beta-cells and
impair glucose-stimulated insulin secretion through activation of
c-Jun N-terminal kinases
Abstract
c-Jun N-terminal kinases (SAPK/JNKs) are activated by inflammatory cytokines, and JNK signaling is
involved in insulin resistance and beta-cell secretory function and survival. Chronic high glucose
concentrations and leptin induce interleukin-1beta (IL-1beta) secretion from pancreatic islets, an event
that is possibly causal in promoting beta-cell dysfunction and death. The present study provides
evidence that chronically elevated concentrations of leptin and glucose induce beta-cell apoptosis
through activation of the JNK pathway in human islets and in insulinoma (INS 832/13) cells. JNK
inhibition by the dominant inhibitor JNK-binding domain of IB1/JIP-1 (JNKi) reduced JNK activity and
apoptosis induced by leptin and glucose. Exposure of human islets to leptin and high glucose
concentrations leads to a decrease of glucose-induced insulin secretion, which was partly restored by
JNKi. We detected an interplay between the JNK cascade and the caspase 1/IL-1beta-converting
enzyme in human islets. The caspase 1 gene, which contains a potential activating protein-1 binding site,
was up-regulated in pancreatic sections and in isolated islets from type 2 diabetic patients. Similarly,
cultured human islets exposed to high glucose- and leptin-induced caspase 1 and JNK inhibition
prevented this up-regulation. Therefore, JNK inhibition may protect beta-cells from the deleterious
effects of high glucose and leptin in diabetes.
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ABSTRACT c-Jun N-terminal kinases (SAPK/JNKs)
are activated by inflammatory cytokines, and JNK sig-
naling is involved in insulin resistance and -cell secre-
tory function and survival. Chronic high glucose con-
centrations and leptin induce interleukin-1 (IL-1)
secretion from pancreatic islets, an event that is possi-
bly causal in promoting -cell dysfunction and death.
The present study provides evidence that chronically
elevated concentrations of leptin and glucose induce
-cell apoptosis through activation of the JNK pathway
in human islets and in insulinoma (INS 832/13) cells.
JNK inhibition by the dominant inhibitor JNK-binding
domain of IB1/JIP-1 (JNKi) reduced JNK activity and
apoptosis induced by leptin and glucose. Exposure of
human islets to leptin and high glucose concentrations
leads to a decrease of glucose-induced insulin secre-
tion, which was partly restored by JNKi. We detected an
interplay between the JNK cascade and the caspase
1/IL-1-converting enzyme in human islets. The
caspase 1 gene, which contains a potential activating
protein-1 binding site, was up-regulated in pancreatic
sections and in isolated islets from type 2 diabetic
patients. Similarly, cultured human islets exposed to
high glucose- and leptin-induced caspase 1 and JNK
inhibition prevented this up-regulation. Therefore,
JNK inhibition may protect -cells from the deleterious
effects of high glucose and leptin in diabetes.—Mae-
dler, K., Schulthess, F. T., Bielman, C., Berney, T.,
Bonny, C., Prentki, M., Donath, M. Y., Roduit, R.
Glucose and leptin induce apoptosis in human -cells
and impair glucose-stimulated insulin secretion through
activation of c-Jun N-terminal kinases. FASEB J. 22,
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Type 2 diabetes mellitus (T2DM) occurs in insulin-
resistant individuals because of -cell insulin secretory
dysfunction and a decrease in -cell mass (1), a major
underlying mechanism thereof being -cell apoptosis
(2, 3). For many years now, evidence has shown that
chronic hyperglycemia and hyperlipidemia, endoplas-
mic reticulum and oxidative stress, cytokines, and au-
toimmunity may trigger the increase in -cell apoptosis
that occurs during the pathogenesis of type 2 diabetes
(4, 5).
In T2DM, hyperglycemic episodes lead to reduction
of insulin secretion as well as insulin stores and to
further -cell destruction in the so-called glucotoxicity
process (6). Various mechanisms of glucose-induced
-cell dysfunction have been studied, including forma-
tion of advanced glycation end products (7), endoplas-
mic reticulum stress (8), reactive oxygen species (6),
direct impairment of insulin gene transcription and
proinsulin biosynthesis (9, 10), and reduced binding
activity of pancreatic duodenal homeobox 1 (11). Re-
cently, we showed up-regulation of the Fas receptor by
elevated glucose per se, leading to cleavage of down-
stream caspases and -cell apoptosis in isolated human
islets (12). We found that interleukin-1 (IL-1) was
expressed and secreted by the -cell itself after chronic
glucose exposure, initiating its self-destruction (13).
Also, in three animal models of T2DM, the Psammomys
obesus (13), the GK rat (14), and the human islet
amyloid polypeptide transgenic rat (15, P. C. Butler,
personnel communication, May 1, 2005), pancreatic
-cell expression of IL-1 in direct association with the
onset of hyperglycemia has been observed.
Leptin, mainly produced and secreted by the adipose
tissue, is an important factor regulating body weight
and glucose homeostasis to the amount of body fat
(16). In “leptin resistance,” high levels of leptin may
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contribute to the dysregulation of the adipo-insular axis
that leads to hyperinsulinemia and promotes T2DM
(16). In vitro, chronic exposure of human islets to
leptin decreases -cell production of interleukin-1 re-
ceptor antagonist (IL-1Ra) and induces IL-1 release
from islet preparation, leading to impaired -cell func-
tion and apoptosis (17). Long-term treatment of -cells
with leptin also decreases insulin biosynthesis (18) and
secretion (19–21).
Activation of members of the mitogen-activated
protein kinase family has been described in several
apoptotic processes including those induced by reactive
oxygen species and IL-1 via Fas (22–24). Although
leptin- and glucose-induced activation of p38 and phos-
phorylated extracellular signal-regulated kinase have
been studied extensively in different cellular systems,
little is known about the role of the c-Jun N-terminal
kinase (JNK) pathway in glucose and leptin signaling. It
has been shown that the JNK pathway is activated by
inflammatory cytokines and free fatty acids in several
tissues under conditions of diabetes and obesity (25).
Inhibition of the JNK pathway in the db/db mouse
model leads to improved insulin resistance and glucose
tolerance (26). Absence of JNK1 in the obese ob/ob
mouse enhances the signaling capacity of the insulin
receptor (27). Also, JNK activation by loss-of function
mutations in the JNK scaffold protein (JIP1/IB1) is a
mediator of cytokine-induced -cell apoptosis (28).
Finally, IB1 has been proposed as a candidate gene
implicated in T2DM (29).
In view of this knowledge, the aim of the present
study was to test the hypothesis that the JNK pathway is
implicated in the action of chronically elevated glucose
and leptin to promote -cell dysfunction and apoptosis.
MATERIALS AND METHODS
Islet isolation and cell culture
Islets were isolated from pancreases of five organ donors at
the Department of Surgery, University of Geneva Medical
Center, as described (30–32). The islet purity was 95%, as
judged by dithizone staining. In some isolations, when this
degree of purity was not primarily achieved by routine
isolation, islets were handpicked. The donors, aged 50–70 yr,
were heart-beating cadaver organ donors, and none had a
previous history of diabetes or metabolic disorders. For
long-term in vitro studies, the islets were cultured on extracel-
lular matrix-coated plates derived from bovine corneal endo-
thelial cells (Novamed Ltd., Jerusalem, Israel), allowing the
cells to attach to the dishes and spread, to preserve their
functional integrity. Islets were cultured in CMRL 1066
medium containing 100 U/ml penicillin, 100 g/ml strepto-
mycin, and 10% fetal calf serum (Invitrogen, Paisley, UK),
hereafter referred to as culture medium. Two days after
plating, when most islets were attached and began to flatten,
the medium was changed to culture medium containing 5.5,
11.1, or 33.3 mM glucose. In some experiments, islets were
additionally cultured with 10 nM recombinant human leptin
(PeproTech, London, UK) or 1 M dominant inhibitor
JNK-binding domain of IB1/JIP-1 (JNKi) and 1 M Tat-
peptide (control), prepared as described before (33). INS
832/13 cells (34) were cultured in complete RPMI-Glutamax
medium containing 11 mM glucose supplemented with 10%
fetal calf serum, 10 mM Hepes (pH 7.4), 1 mM sodium
pyruvate, and 50 M -mercaptoethanol. INS 832/13 cells
were incubated for 18 h in complete culture medium at 5.5 or
20 mM glucose in the absence or presence of 10 nM recom-
binant human leptin, 1 M JNKi, and 1 M Tat-peptide
(control).
Western blot analysis and protein kinase assays
Islets were cultured in culture medium in nonadherent
plastic dishes. One day after isolation, medium was changed,
and groups of 200 islets were incubated for 18 h in culture
medium conditions as described above.
At the end of the incubations, islets were washed in PBS,
suspended in 100 l of lysis buffer containing 20 mM Tris
acetate, 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 50 mM
NaF, 1% Triton X-100, 5 mM sodium pyrophosphate, 10 mM
-glycerophosphate, 1 mM dithiothreitol (DTT), 1 mM
Na3VO4, 1 mM 4-nitrophenol phosphate, 1 mM benzamidine,
and 4 g/ml leupeptin and were lysed for 30 min on ice. The
detergent-insoluble material was pelleted by centrifugation at
15,000 rpm for 5 min at 4°C. The supernatants containing
whole cell lysates were used for Western blotting or whole cell
lysate kinase assays.
For Western blot analysis, equivalent amounts of protein
from each treatment group were run on 15% sodium dodecyl
sulfate (SDS) -polyacrylamide gels. Proteins were electrically
transferred to nitrocellulose filters and incubated with rabbit
anti-caspase 1 (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA) or rabbit anti-actin (Cell Signaling Technology
Inc., Beverly, MA, USA) antibodies followed by incubation
with horseradish-peroxidase-linked anti-rabbit IgG peroxi-
dase-conjugated antibodies (Santa Cruz Biotechnology Inc.).
Immune complexes were detected by chemiluminescence
using LumiGLO (Cell Signaling Technology Inc.).
For protein kinase assays, 1 g of glutathione S-transferase
(GST) -cJun (amino acids 1–89) coupled to glutathione-
agarose beads was added to cellular extracts and incubated
for 3 h at 4°C. The beads were washed 3 with washing buffer
(lysis buffer with 0.1% Triton X-100 instead of 1% Triton
X-100) and 2 with kinase buffer (20 mM HEPES, pH 7.5; 20
mM glycerophosphate; 10 mM MgCl2; 1 mM DTT; and 50 M
Na3VO4). Finally, they were resuspended in kinase buffer
supplemented with 5 Ci of [-33P]ATP. After incubation at
30°C for 30 min, reaction products were separated by SDS-
polyacrylamide gel electrophoresis on a denaturing 10%
polyacrylamide gel. The gels were stained with Coomassie
Blue to check for equal loading of the samples, dried, and
subsequently exposed to X-ray films. Density of the bands was
analyzed using Labworks 4.5 software (BioImaging Systems,
Upland, CA, USA).
-Cell apoptosis
Free 3-hydroxy strand breaks resulting from DNA degrada-
tion were detected by the terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick-end labeling (TUNEL) technique
according to the manufacturer’s instructions (In Situ Cell
Death Detection Kit, AP; Boehringer Mannheim, Mannheim,
Germany) as described before (13). To detect the -cells,
islets were incubated with guinea pig anti-insulin antibody
(DakoCytomation A/S, Copenhagen, Denmark), followed by
detection using the streptavidin-biotin-peroxidase complex
(Zymed Laboratories, Burlingame, CA, USA). The samples
were immediately evaluated by fluorescence microscopy for
positively stained apoptotic nuclei. To determine apoptosis in
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INS 832/13 cells, cells were double-stained with the fluores-
cent DNA-staining dyes Hoechst 33342 and propidium iodide.
Stained nuclei were immediately visualized by fluorescence
microscopy (Axiovert 25; Zeiss, Oberkochen, Germany). For
each experiment a minimum of 1000 cells were counted
using an inverted fluorescence microscope. Cells were de-
fined as apoptotic when they exhibited a condensed nuclear
chromatin or a fragmented nuclear membrane when visual-
ized with Hoechst 33342.
Caspase 1 immunostaining of islets and pancreases
Islets were incubated for 18 h in culture medium containing
5.5 or 33.3 mM glucose without or with 10 nM recombinant
human leptin, 1 M JNKi, or 1 M Tat-peptide. At the end of
the incubations, islets were washed in PBS, fixed in Bouin
solution for 15 min, and resuspended in 40 l of 2% melted
agarose in PBS (40°C), followed by rapid centrifugation and
paraffin embedding. Pancreases from routine necropsies
were immersion-fixed in formalin, followed by paraffin em-
bedding. Sections were deparaffinized and rehydrated, en-
dogenous peroxidase was blocked by submersion in 0.3%
H2O2 for 15 min, and sections were incubated in methanol
for 4 min. Sections were incubated with a 1:50 dilution of
anti-caspase 1 (Santa Cruz Biotechnology Inc.) antibody,
detected by donkey anti-rabbit Cy3-conjugated antibody
(Jackson ImmunoResearch Laboratories, West Grove, PA,
USA), and double-stained for insulin with pig anti-insulin
antibody (DakoCytomation A/S) and fluorescein isothiocya-
nate-conjugated donkey anti-guinea pig antibody (Jackson
ImmunoResearch).
NF-B activation
Human islets were cultured as described above and washed
with PBS. Activation of the NF-B complex was quantified
with an ELISA-based kit (Trans-AM NF-B; Active Motif LLC,
Carlsbad, CA, USA) using attached oligonucleotides corre-
sponding to an NF-B consensus binding site and detected by
an anti-p65 subunit antibody according to the manufacturer’s
instructions. INS 832/13 cells were cultured in RPMI-Glu-
tamax medium before transfection with Lipofectamine 2000,
with a pNFkB-Luc reporter vector encoding the firefly lucif-
erase gene as the reporter gene and with an internal control
pRL-SV40 vector encoding the Renilla luciferase 24 h after the
transfection. A dual luciferase assay (Promega Corp., Madi-
son, WI, USA) was then performed to measure NF-B activity
accordingly to the manufacturer’s instructions.
RNA extraction and quantitative reverse transcription
(RT) -polymerase chain reaction (PCR)
Total RNA was extracted from the cultured islets by using an
RNeasy Mini Kit (Qiagen, Basel, Switzerland), and RT-PCR
was performed using the SuperScript Double-Stranded cDNA
Synthesis Kit according to the manufacturer’s instructions
(Life Technologies, Inc., Gaithersburg, MD, USA). A quanti-
tative PCR system was used to perform RT-PCR with a
commercial kit (Light Cycler DNA Master SYBR Green I;
Roche Diagnostics, Basel, Switzerland). Primers used were
5-AGAGTCGCGCTGTAAGAAGC-3 and 5-TGGTCTTGTC-
ACTTGGCATC-3 (-tubulin), 5-TACGGGTCCTGGCATCT-
TGT-3 and 5-CCATTTGTGTTGGGTCCAGC-3 (cyclophilin),
5-TTCTGTGGAAAAGAGGCAGGC-3 and 5-GCTCCGTTTT-
AGCTCGTTCCT-3 (c-Myc), 5-CCCAGTCTGCATAGAAGG-3
and 5TGATACACTCCAAGCGGAGAC3 (c-Fos), and 5-AAAT-
CTCACTGCTTCGGACAT-3 and 5-GGGCAGTTCTTGGTAT-
TCAAC-3 (caspase 1).
Insulin release and content
To determine acute insulin release in response to glucose
stimulation, islets were washed in Krebs-Ringer bicarbonate
(KRB) buffer supplemented with 0.5% BSA (Sigma-Aldrich
Corp., St. Louis, MO, USA) containing 2.8 mM glucose (pH
7.4) and preincubated for 30 min at 37°C in air in the same
buffer. KRB was then discarded and replaced with fresh
buffer containing 2.8 mM glucose, and islets were incubated
for 1 h to assess basal secretion, followed by additional 1-h
incubation in KRB containing 16.7 mM glucose. Incubates
were collected and frozen for insulin assays. Islets were
washed with PBS and extracted with 0.18 N HCl in 70%
ethanol for 24 h at 4°C. Acid-ethanol extracts were collected
for determination of insulin content. Insulin was determined
by a human insulin RIA kit (CIS Bio International, Gif-Sur-
Yvette, France).
Evaluation and statistical analysis
Samples were evaluated in a randomized manner by a single
investigator (K.M.) who was blinded to the treatment condi-
tions. Care was taken to score islets of similar size. Some larger
islets did not completely spread and were several cells thick.
Such larger islets were excluded because a monolayer is a
prerequisite for single cell evaluation. Saisam software (Mi-
crovision Instruments, Evry, France) was used to measure the
areas. Data were analyzed by Student’s t test or by ANOVA
with a Bonferroni correction for multiple group comparisons.
RESULTS
JNK inhibitor protects from glucose- and leptin-
induced -cell apoptosis and dysfunction
Human islets were cultured on extracellular matrix-
coated plates for 4 days, and the -cell line INS 832/13
was cultured for 18 h in the presence of increasing
glucose concentrations (5.5, 11.1, and 33.3 mM) or 5.5
mM glucose with 10 nM leptin with or without 1 M
JNKi. Glucose dose dependently induced -cell apopto-
sis in human islets (Fig. 1A, C). In contrast, in INS
832/13 cells, baseline apoptosis was minimal at 11.1
mM glucose and increased at 5.5 and 33.3 mM (Fig.
1B). In both models, leptin induced -cell apoptosis
(2.6-fold in human islets and 3.3-fold in INS832/13
cells, compared with untreated islets at 5.5 mM glucose,
P	0.001) (Fig. 1A, B). Addition of 1 M JNKi to the
culture medium for 1 h before glucose or leptin
exposure through the whole culture period protected
from glucose- and leptin-induced -cell apoptosis (Fig.
1A–C). A radioactive kinase assay showed that both
leptin and high glucose induced JNK activity in human
islets, which was prevented when JNKi was present 1 h
before addition of either glucose or leptin (Fig. 1D).
Induction of JNK activity was increased either by
leptin (204.2
24.5%) or by glucose (170.7
15.7%)
compared with the control 5.5 mM glucose (100%).
Addition of JNKi peptide before exposure to leptin or
high glucose decreased the induced JNK activities to
123.7 
 12.5 and 111.5 
 9.5% for leptin and high
glucose, respectively.
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In human islets, the changes in -cell apoptosis were
accompanied by leptin (2.2-fold) and glucose (4-fold)
-induced reductions in glucose-stimulated insulin secre-
tion (GSIS) compared with baseline glucose at 5.5 mM
(Fig. 1E) together with 2.6- and 3.3-fold reductions in
islet insulin content by leptin and 33.3 mM glucose,
respectively (Fig. 1F). Addition of JNKi to the culture
medium protected the impairing effects of leptin and
33.3 mM glucose on both GSIS and islet insulin content
(Fig. 1E, F) (P	0.01).
Inhibition of JNK protects from caspase 1 activation
in -cells
The mechanisms leading to JNK-dependent -cell apo-
ptosis induced by high glucose and leptin were studied
by analyzing expression levels of caspase 1, also named
interleukin-1-converting enzyme (ICE). Human iso-
lated islets were cultured for 48 h at 5.5, 11.1, or 33.3
mM glucose or in the presence of 10 nM leptin with or
without 1 M JNKi. High glucose and leptin increased
caspase 1 on the mRNA level (1.7-fold at 11.1 mM and
2.2-fold at 33.3 mM glucose and 1.5-fold at 10 nM
leptin, P	0.05) (Fig. 2A). Additional treatment of the
islets with 1 M JNKi completely blocked the increase
of caspase 1 mRNA (Fig. 2A). Expression of caspase 1
protein was increased after exposure of human islets to
high glucose and to leptin (Fig. 2B), and inhibition of
JNK activity restored basal levels of caspase 1 in glucose-
treated islets and reduced the effect of leptin on
caspase 1 expression (Fig. 2B, C). To analyze cellular
localization of caspase 1 in islets, we used sections from
Figure 1. Glucose and leptin induce -cell apoptosis and impaired function
through activation of c-Jun N-terminal kinases. Human islets were cultured on
extracellular matrix-coated dishes for 4 days (A, C) and INS 832/13 cells were
cultured for 18 h (B) at 5.5, 11.1, or 33.3 mM glucose or 5.5 mM glucose plus 10
nM recombinant human leptin with or without 1 M JNKi. A) Percentage of
TUNEL-positive -cells normalized to control incubations at 5.5 mM glucose alone
(100%; corresponds in absolute values to 0.4
0.05% TUNEL-positive -cells). The
mean number of islets scored was 41 for each treatment condition from each
donor. B) Percentage of INS 832/13 cells presenting a condensed nuclear
chromatin or a fragmented nuclear membrane, visualized by Hoechst staining and
normalized to control incubations at 5.5 mM glucose alone. C) Double immuno-
staining for -cell apoptosis with the TUNEL assay in black and anti-insulin in
brown in control (5.5 mM glucose) and glucose-treated human islets with (33.3
mM glucoseJNKi) or without (33.3 mM glucose) addition of 1 M JNKi. Black arrows mark TUNEL-positive -cells.
D) Measurement of JNK activity from human islet lysates cultured for 18 h in suspension at 5.5 or 33.3 mM glucose with
or without leptin or JNKi. Upper panel, phosphorylated GST-cJun as revealed by Western blotting radioactive assay; lower
panel, input of GST-cJun stained with Coomassie Blue. The blot shows a representative blot of five experiments from five
islet donors. The density of the phosphorylated (P) GST-cJun band was quantified by scanning and expressed as a
percentage relative to control (5.5 mM glucose) E) Basal and glucose-stimulated insulin secretion denote the amount
secreted during successive 1-h incubations at 2.8 (basal) and 16.7 (stimulated) mM glucose after the 4-day culture period
and expressed as secreted insulin. F) Insulin content from the same islets. Islets were isolated from five organ donors
(A, C, E, F) or results are from three separate experiments (B). Results are means 
 se. *P 	 0.05 compared with untreated
controls; **P	 0.05 compared with leptin-treated islets; #P	 0.05 compared with 11.1 mM glucose-treated islets; P	 0.05
compared with 33.3 mM glucose-treated islets.
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cultured human islets and double-stained them for
caspase 1 and insulin. Figure 2Ca–f, shows representa-
tive images from one experiment of five from five
separate donors. No caspase 1 staining was observed in
control islets cultured at 5.5 mM glucose, but 48 h of
culture with leptin or 33.3 mM glucose induced expres-
sion of caspase 1 in -cells. On the basis of these in vitro
studies, we expected caspase 1 expression also in islets
of patients with T2DM, as a result of hyperglycemia.
Caspase 1 expression was studied in sections of pancre-
ases from four patients with poorly controlled type 2
diabetes, all with documented fasting blood glucose
higher than 8 mM. Double immunostaining of the
pancreatic sections for caspase 1 and insulin revealed
a b
c d
e f
g h
i j
a b
c d
Figure 2. Inhibition of JNK protects from activation of caspase 1 in -cells. Human
islets were cultured for 48 h in suspension at 5.5, 11.1, or 33.3 mM glucose or 5.5 mM
glucose plus 10 nM recombinant human leptin with or without 1 M JNKi for 48 h.
A) Quantitative RT-PCR analysis of caspase 1 expression, compared with tubulin,
expressed as relative levels to control at 5.5 mM glucose. B) Representative immuno-
blotting of caspase 1 and actin out of four experiments from four donors. Actin was
used as the loading control. The density of expression levels was quantified after
scanning, normalized to actin levels, and expressed as a change from the 5.5 mM
control. C, D) Double immunostaining of cultured islets at 5.5 mM glucose (Ca,b),
treated with leptin (Cc,d), leptin and JNKi (Ce,f ), 33.3 mM glucose (Cg,h), or 33.3 mM glucose  JNKi (Ci,j) and
pancreatic sections from a nondiabetic control (Da,b) or a patient with T2DM (Dc,d) with anti-insulin (Ca,c,e ; Da,c) and
anti-caspase 1 (Cb,d,f ; Db,d) antibodies. E) Quantitative RT-PCR analysis of caspase 1 expression in isolated islets from three
controls and from three patients with T2DM and expressed relative to controls. Results are means 
 se. *P 	 0.05
compared with untreated (A) or nondiabetic (E) controls (5.5 mM glucose); **P 	 0.05 compared with leptin-treated
islets; #P 	 0.05 compared with 11.1 mM glucose-treated islets; P 	 0.05 compared with 33.3 mM glucose-treated islets.
1909JNK ACTIVATION IN HUMAN -CELLS
expression of the caspase in almost all -cells in the
T2DM sections of pancreases of T2DM, but no signal
was observed in the control sections (Fig 2D). In
parallel, we analyzed caspase 1 levels in isolated islets
from three control and three age- and weight-matched
organ donors with T2DM. Caspase 1 mRNA expression
was 6.23-fold increased in the diabetic islets (Fig. 2E)
(P	0.05).
Glucose but not leptin up-regulates c-fos and c-myc
transcripts and enhances activator protein-1 (AP-1)
and NF-B activities in -cells
Although we found similar activation of JNK induced by
high glucose and leptin, downstream targets were dif-
ferently modulated. We measured mRNA expression
levels of downstream targets of JNK, c-fos, and c-myc in
cultured human islets. Glucose dose dependently in-
duced c-fos up-regulation; there were 1.9 
 0.1- and
3.1 
 0.5-fold increases in c-fos mRNA by 11.1 and 33.3
mM glucose, respectively (P	0.05), which were pre-
vented by JNKi (Fig. 3A). In contrast, leptin treatment
of the islets had no effect on c-fos expression. Then, we
measured c-myc in islets and found 2.2 
 0.2- and 3.2 

0.6-fold increases in c-myc mRNA by 11.1 and 33.3 mM
glucose, respectively (P	0.05), which were inhibited by
JNKi. Leptin showed no significant effect on c-myc (Fig.
3B). Results obtained in the INS 832/13 cells line
support the hypothesis of diverse downstream activators
for glucose and leptin. AP-1 activity, performed by dual
luciferase assay, was 5.9-fold increased by glucose and
decreased in the presence of JNKi (P	0.05). In con-
trast, leptin failed to induce AP-1 activity (Fig. 3C).
Finally, activation of the transcription factor NF-B was
assessed. This nuclear factor was 2.3 
 0.4- and 2.1 

0.4-fold activated by 33.3 mM glucose in human islets
(Fig. 3D) and INS 832/13 cells (Fig. 3E), respectively,
but JNKi failed to inhibit the activation. Again, leptin
did not activate NF-B in both cell types. Altogether
these results are compatible with the possibility that
AP-1, c-myc, and NF-B are implicated in -cell gluco-
toxicity but not in the action of leptin.
DISCUSSION
The deleterious effects of chronically elevated glucose
levels (11, 12, 35–47) as well as repetitively high post-
prandial glucose (48) on the pancreatic -cell and its
role in the pathophysiology of diabetes are well estab-
Figure 3. Glucose but not leptin up-
regulates c-fos, c-myc, and NF-B in
-cells. A, B) Human islets were cul-
tured in a suspension at 5.5, 11.1, or
33.3 mM glucose or 5.5 mM glucose
plus 10 nM recombinant human lep-
tin with or without 1 M JNKi for
48 h. Quantitative RT-PCR analysis of
c-fos (A) and c-myc (B) expression was
normalized for tubulin, and the re-
sults are expressed as mRNA levels
relative to control incubations at 5.5
mM glucose. C) AP-1 activity in INS
832/13 cells. Cells were transiently
transfected with a luciferase reporter
gene fused to an AP-1 consensus binding site. Then cells were cultured in 5.5 or 20 mM glucose or 5.5 mM glucose plus
10 nM recombinant human leptin with or without 1 M JNKi for 18 h. Luciferase expression was assessed, and results are
expressed as mean 
 se normalized to control incubations at 5.5 mM glucose. Results represent data from three
independent experiments. D, E) Relative NF-B activity detected by an anti-p65 subunit antibody in human islets (D) and
INS832 cells (E). Results are means 
 se from five experiments from five different donors for human islets experiments
and from three distinct experiments for INS 832/13 cells. *P 	 0.05 compared with untreated controls; #P 	 0.05
compared with 11.1 mM glucose-treated islets; P 	 0.05 compared with to 33.3 mM glucose-treated islets.
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lished, causing impaired -cell function as well as
increased apoptosis. Therefore, preventing the -cell
from these effects is a target to treat diabetes. Previously
we have shown that glucose induces production of the
proinflammatory cytokine IL-1 and activation of Fas in
human islets (12, 13). IL-1 and Fas induce -cell death
and activate the JNK signaling cascade (49, 50). This
study shows that high glucose-induced apoptosis is also
related to JNK activation. One explanation of JNK
activation could be that isolation of the islets renders
them susceptible to activation of stress pathways (51).
Baseline JNK activation was variable in the different
human islet isolation procedures used, possibly depen-
dent on the islet isolation procedure itself. Neverthe-
less, JNK activity was always further up-regulated by
glucose not only in isolated islets but also in the
pancreatic -cell line INS 832/13 (data not shown).
Interestingly, treatment of islets with a specific inhibitor
of JNK blocked glucose-induced -cell apoptosis and
normalized glucose-stimulated insulin secretion, which
was markedly impaired by glucotoxicity.
Leptin is also a proinflammatory cytokine (52). It has
a proapoptotic effect on human -cells with chronic
exposure (17, 53), and it shifts the balance of IL-1/
IL-1Ra toward the proinflammatory IL-1 (17). The
concentration of leptin used is similar to that used in
other in vitro studies (54, 55) and is in the upper range
of those measured in obese people (56). As for chronic
high glucose, similar deleterious effects were induced
by exposure of human islets to leptin, and JNK inhibi-
tion also restored normal -cell function and reduced
apoptosis. This observation is of interest in view of the
fact that recent studies suggest that hyperleptinemia
plays a role in obesity-associated diseases (57). Leptin
induces stimulation of inflammatory reactions as well as
oxidative stress in many cell types, including -cells.
Leptin also impairs islet function in rat, mouse, and
human -cells (19, 21, 58–60) and is ineffective in
leptin receptor-deficient db/db mice (58) and fa/fa rats
(19). In contrast, others have documented an antiapo-
ptotic effect of leptin with respect to free fatty acid-
induced apoptosis of rodent islets in vitro (61). This
result might be due to the lipid-lowering effect of
leptin, which is anticipated to reduce “lipotoxicity.”
Chronically hyperleptinemic rats develop hypoglyce-
mia with reversible -cell dysfunction by depletion of
tissue lipids (62). Nonetheless, there is evidence for a
toxic rather than a beneficial effect of hyperleptinemia
in the obese/diabetic situation (63). Obesity in humans
is the main risk factor for the development of diabetes;
it is accompanied by increased circulating leptin and
cytokine levels. Interestingly, leptin administration ac-
celerates the onset and progression of autoimmune
diabetes in NOD mice (64), providing a link between
type 1 and type 2 diabetes. Furthermore, leptin levels
are increased in T2DM as a stress response, indepen-
dently of obesity and sex (65).
In this study, we detected JNK activation as a com-
mon pathway, which mediates glucose- and leptin-
induced -cell apoptosis and impaired function in
human isolated islets as well as in a -cell line. Both
compounds also induced up-regulation of caspase 1,
the enzyme that promotes the maturation of pro-IL-1
into its biologically active proinflammatory form. Addi-
tion of a cell-permeable specific JNK inhibitory peptide
inhibited apoptosis, restored -cell function, and pre-
vented caspase 1 up-regulation. This suggests a link
between JNK and caspase 1, at least in part via the
transcription factor AP-1, which may target the re-
sponse elements in the caspase 1 gene promoter. On
JNK activation, in the presence of high levels of caspase
1, pro-IL-1 could be processed into its active form. In
contrast, blocking of JNK would lead to down-regula-
tion of caspase 1 and IL-1 production. IL-1 itself
induces JNK (49) and caspase 1 (66) up-regulation in
-cells. This leads to further IL-1 maturation and
apoptosis (67). An important substrate of JNK is the
cJun protein, which is phosphorylated on JNK activa-
tion. cJun protein is a component of transcription
factor AP-1, which regulates many cellular processes,
including apoptosis. Interestingly, two potential AP-1
binding sites (68) are present in the caspase 1 promoter
and, if active, could provide a link between glucose-
induced JNK activation and up-regulation of caspase 1.
It will be of interest to determine whether these
putative AP-1 binding sites are implicated in the
mechanisms of glucose-induced -cell apoptosis. As
AP-1 is not increased by leptin, another transcription
factor may be involved in the regulation of the caspase
1 gene.
In conclusion, our results provide new insights into
the mechanisms of glucotoxicity and leptin-induced
-cell apoptosis, by showing that both chronic high
glucose and leptin activate JNK and induce caspase
1/ICE, the enzyme that converts pro-IL-1 to IL-1. In
addition, we show that ICE is induced in islets from
patients with T2DM. Because JNK inhibition reversed
the toxic actions of high glucose and leptin on the
-cell, the data support the concept that therapeutic
approaches designed to block JNK activation could be
helpful not only to improve insulin resistance (26) but
also to prevent a progressive decrease of -cell mass and
to restore -cell function.
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